{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:50:57Z","timestamp":1769313057507,"version":"3.49.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.2146\/ajhp100493","type":"journal-article","created":{"date-parts":[[2011,7,22]],"date-time":"2011-07-22T22:05:43Z","timestamp":1311372343000},"page":"1409-1418","source":"Crossref","is-referenced-by-count":8,"title":["Denosumab for treatment of postmenopausal osteoporosis"],"prefix":"10.1093","volume":"68","author":[{"given":"Mona","family":"Chitre","sequence":"first","affiliation":[{"name":"Clinical Services, Strategy and Policy, Excellus BlueCross BlueShield, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shechter","sequence":"additional","affiliation":[{"name":"Scientific Affairs"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Grauer","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc., Thousand Oaks, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106030711500_b1-0681409","first-page":"1","volume-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","year":"2010"},{"key":"key\n\t\t\t\t2019041106030711500_b2-0681409","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041106030711500_b3-0681409","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0002-9343(91)90512-V","article-title":"Consensus development conference: pro-phylaxis and treatment of osteoporosis","volume":"90","year":"1991","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041106030711500_b4-0681409","volume-title":"Prolia (denosumab) full prescribing information","year":"2010"},{"key":"key\n\t\t\t\t2019041106030711500_b5-0681409","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b6-0681409","volume-title":"America\u2019s bone health: the state of osteoporosis and low bone mass in our nation","year":"2002"},{"issue":"(suppl 11)","key":"key\n\t\t\t\t2019041106030711500_b7-0681409","first-page":"S290","article-title":"An integrated approach: bisphosphonate management for the treatment of osteoporosis","volume":"13","author":"Owens","year":"2007","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t2019041106030711500_b8-0681409","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-004-2222-2","article-title":"Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly\u2014a 12- and 22-year follow-up of 257 patients","volume":"76","author":"Hasserius","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041106030711500_b9-0681409","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b10-0681409","first-page":"1","author":"Prevention and management of osteoporosis: WHO technical report series 921","year":"2003"},{"key":"key\n\t\t\t\t2019041106030711500_b11-0681409","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019041106030711500_b12-0681409","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bone.2009.07.086","article-title":"Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures","volume":"45","author":"Shi","year":"2009","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041106030711500_b13-0681409","unstructured":"World Health Organization. FRAX: WHO fracture risk assessment tool. www.shef.ac.uk\/FRAX\/tool.jsp (accessed 2011 Apr 14)."},{"key":"key\n\t\t\t\t2019041106030711500_b14-0681409","volume-title":"Bone health and osteoporosis: a report of the Surgeon General","year":"2004"},{"key":"key\n\t\t\t\t2019041106030711500_b15-0681409","first-page":"182","volume-title":"Musculoskeletal conditions in the United States","author":"Praemer","year":"1992","edition":"2nd ed"},{"key":"key\n\t\t\t\t2019041106030711500_b16-0681409","unstructured":"National Committee for Quality Assurance. The state of health care quality: reform, the quality agenda, and resource use. www.ncqa.org\/portals\/0\/state%20of%20health%20care\/2010\/SOHC%202010%20-%20Full2.pdf (accessed 2011 Apr 18)."},{"key":"key\n\t\t\t\t2019041106030711500_b17-0681409","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for post-menopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int"},{"issue":"(suppl 2)","key":"key\n\t\t\t\t2019041106030711500_b18-0681409","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","article-title":"Impact of osteoporosis treatment adherence on fracture rates in North America and Europe","volume":"122","author":"Siris","year":"2009","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041106030711500_b19-0681409","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2008.09.006","article-title":"Effectiveness of bisphosphonate therapy in a community setting","volume":"44","author":"Feldstein","year":"2009","journal-title":"Bone"},{"issue":"(6937)","key":"key\n\t\t\t\t2019041106030711500_b20-0681409","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041106030711500_b21-0681409","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S0029665108007003","article-title":"Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment","volume":"67","author":"Lanham-New","year":"2008","journal-title":"Proc Nutr Soc"},{"key":"key\n\t\t\t\t2019041106030711500_b22-0681409","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2007-1876","article-title":"Bone mineral density changes during the menopause transition in a multiethnic cohort of women","volume":"93","author":"Finkelstein","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041106030711500_b23-0681409","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"issue":"(6717)","key":"key\n\t\t\t\t2019041106030711500_b24-0681409","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclasto-genesis, lymphocyte development and lymphnode organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041106030711500_b25-0681409","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t2019041106030711500_b26-0681409","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019041106030711500_b27-0681409","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019041106030711500_b28-0681409","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early post-menopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041106030711500_b29-0681409","article-title":"The pharmacokinetics of denosumab (AMG162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass","volume":"20","author":"Peterson","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b30-0681409","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2010.02.064","article-title":"A single dose study of denosumab in patients with various degrees of renal impairment","author":"Block","year":"2010"},{"key":"key\n\t\t\t\t2019041106030711500_b31-0681409","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041106030711500_b32-0681409","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041106030711500_b33-0681409","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041106030711500_b34-0681409","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b35-0681409","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041106030711500_b36-0681409","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b37-0681409","unstructured":"Boonen S McClung M Minisola S . Effect of denosumab on the incidence of hip, new vertebral, and non-vertebral fractures over 3 years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM study. www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=da35831c-de93-4607-8b12-b7fcaf42f45d (accessed 2011 Apr 18)."},{"key":"key\n\t\t\t\t2019041106030711500_b38-0681409","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","article-title":"Bisphosphonates in the management of postmenopausal osteoporosis\u2014optimizing efficacy in clinical practice","volume":"3","author":"Bock","year":"2008","journal-title":"Clin Interv Aging"},{"key":"key\n\t\t\t\t2019041106030711500_b39-0681409","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041106030711500_b40-0681409","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00198-009-1023-x","article-title":"Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass","volume":"21","author":"Kendler","year":"2010","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041106030711500_b41-0681409","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effects of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041106030711500_b42-0681409","article-title":"Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial","author":"Chapurlat","year":"2010"},{"key":"key\n\t\t\t\t2019041106030711500_b43-0681409","volume-title":"Xgeva (denosumab) full prescribing information","year":"2010"},{"key":"key\n\t\t\t\t2019041106030711500_b44-0681409","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041106030711500_b45-0681409","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041106030711500_b46-0681409","volume-title":"Reclast (zoledronic acid) full prescribing information","year":"2009"},{"key":"key\n\t\t\t\t2019041106030711500_b47-0681409","volume-title":"Boniva Injection (ibandronate sodium) full prescribing information","year":"2009"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/15\/1409\/28349834\/ajhp1409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T06:35:29Z","timestamp":1560407729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/15\/1409\/5129244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":47,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100493","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,8,1]]},"published":{"date-parts":[[2011,8,1]]}}}